Immatics N.V. (IMTX)
$6.83-5.27%Close
SELLCRISIS · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $916M
- Beta
- 1.36
- P/E (TTM)
- -3.83
- Short % float
- 3.29%
- Days to cover
- 4.2
- SI change
- -16.8%
- 1W
- -8.93%
- 1M
- -20.77%
- vs SPY 1W
- -8.79%
- vs SPY 1M
- -23.27%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 3
- VALUE
- 2
- GROWTH
- 19
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-28.2%
REV YoY-
ROE-47.0%
EPS YoY-
ROA-42.5%
GROSS100
OP-544
NET-495
[VALUATION]
P/E TTM-3.83
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.09
P/FCF-
EV/EBITDA-3.09
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E3.65
ALTMAN Z-
CURR RATIO7.54
ND/EBITDA-
BETA1.36
Company news
FAQ
- What is LOPJLB’s current signal on IMTX?
- LOPJLB’s latest quantitative signal on Immatics N.V. (IMTX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IMTX in?
- Immatics N.V. (IMTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Immatics N.V. (IMTX) do?
- Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's A…